Phase I clinical trial to evaluate the tolerability, pharmacodynamics and pharmacokinetics of LW231 tablets in healthy subjects and patients with chronic hepatitis B by single-center, randomized, double-blind, placebo-controlled, multiple-dose, single-dose and multiple-dose
Latest Information Update: 25 Oct 2024
At a glance
- Drugs LW 231 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
Most Recent Events
- 09 Jan 2024 New trial record